Showing results (261-270 of 491) with videos related to
Sort By:
Pageof 50
The American Journal of Medicine|July 2, 2013
Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patientsLinong Ji, Dayi Hu, Changyu Pan, et al.European Heart Journal|December 5, 2013
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AFWilliam Schuyler Jones, Anne S Hellkamp, Jonathan Halperin, et al.American Heart Journal|November 7, 2015
A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS)Derek P Chew, Carolyn M Astley, Heather Luker, et al.American Heart Journal|June 23, 2014
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trialJan H Cornel, E Magnus Ohman, Benjamin Neely, et al.Circulation|June 6, 2019
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery DiseaseKelley R Branch, Jeffrey L Probstfield, John W Eikelboom, et al.Archives of Internal Medicine|October 29, 2003
Predictors of hospital mortality in the global registry of acute coronary eventsChristopher B Granger, Robert J Goldberg, Omar Dabbous, et al.European Heart Journal|March 17, 2010
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspectiveFrederick A Spencer, Gilles Montalescot, Keith A A Fox, et al.Journal of the American Heart Association|March 21, 2015
Efficacy and safety of vorapaxar as approved for clinical use in the United StatesGiulia Magnani, Marc P Bonaca, Eugene Braunwald, et al.Journal of the American College of Cardiology|October 30, 2007
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trialShamir R Mehta, Christopher B Granger, John W Eikelboom, et al.American Heart Journal|March 3, 2009
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of riskCampbell D Joyner, Ron J G Peters, Rizwan Afzal, et al.Pageof 50